Last reviewed 2026-06-10 · How we verify

Dry eye disease — Treatment Landscape & Competitive Intelligence

Dry eye disease (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Dry eye disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Alcon Labs Inc · 1 drug in Dry eye disease
2. Bausch & Lomb Incorporated · 1 drug in Dry eye disease
3. Bausch Health · 1 drug in Dry eye disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Dry eye disease:

• Dry eye disease treatment updates — RSS
• Dry eye disease treatment updates — Atom
• Dry eye disease treatment updates — JSON

Cite this brief

Drug Landscape (2026). Dry eye disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/dry-eye-disease. Accessed 2026-06-10.

Related

• Dry eye disease full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing